% | $
Quotes you view appear here for quick access.

Elite Pharmaceuticals, Inc. Message Board

  • amabloes amabloes Jan 26, 2013 1:00 PM Flag

    Elite in the news global data

    GlobalData estimates that the global osteoarthritis (OA) pain therapeutics market was valued at $4.9 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.3% over the next seven years, to reach $6.1 billion by 2017. This slow growth is primarily attributed to low levels of treatment-seeking behavior, disease awareness and the usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs.

    Abbott Laboratories, Adolor Corporation, Cephalon, Inc., Endo Pharmaceuticals, Elite Pharmaceuticals, Glenmark Pharmaceuticals, Grunenthal GMBH, Johnson & Johnson Pharmaceuticals Ltd., Pfizer, Inc., SantaSolve AS, and Sanofi-aventis are going to be the key players in the OA pain market. GlobalData has profiles of all these companies as they hold important pipeline drugs in late stage development for OA Pain treatment.

    Sentiment: Strong Buy

0.305-0.008(-2.71%)May 3 3:59 PMEDT